-
"Diversity, Equity and Inclusion" Page Renewal
Introducing Eisai DE&I: Now and the Future
Learn more
"Diversity, Equity and Inclusion" Page Renewal
Introducing Eisai DE&I: Now and the Future
-
Looking Back on 10 Years Since the Commencement of Free Provision of DEC Tablets
Eisai Staff in Charge Talks About Overcoming Challenges on the Uneven Road by Building Trust in Global Partnerships
-
Scientists Discuss the Development of a New Treatment for the Elimination of Mycetoma
-
New Innovation Page Launch
-
June 3, 2024
EISAI NAMED TO LIST OF THE TIME 100 MOST INFLUENTIAL COMPANIES
-
June 3, 2024
-
June 3, 2024
-
May 27, 2024
“LEQEMBI®” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in South Korea
-
May 23, 2024
EISAI SHOWCASES ONCOLOGY PORTFOLIO AND PIPELINE AT ASCO 2024
-
May 31, 2024
-
May 22, 2024
-
May 21, 2024
IR “Notice of Convocation of the 112th Ordinary General Meeting of Shareholders”
-
May 17, 2024
IR “Annual Financial Results Briefing for the Fiscal Year Ended March 31, 2024 [Material, Webcast]”
-
May 15, 2024
IR “Annual Financial Report for the Fiscal Year Ended March 31, 2024”
-
June 3, 2024
The Naito Museum of Pharmaceutical Science and Industry Listed as “Registered Museum”
-
April 8, 2024
-
October 13, 2023
-
March 9, 2023
Warning Against Solicitation, Fraudulent Emails, etc. that Use the Name of Eisai or Related Parties
-
February 17, 2023
EISAI SUPPORTS RELIEF EFFORTS FOR EARTHQUAKE IN TURKEY AND SYRIA
Sustainability
30 countries 2.28 billion tablets
Number of countries supplied with lymphatic filariasis treatment
and volume supplied (as of March 2024)
Eisai is promoting initiatives for improving access to medicines to contribute to people in developing and emerging countries